Zobrazeno 1 - 10
of 168
pro vyhledávání: '"Afisi S. Ismaila"'
Autor:
Afisi S. Ismaila, Kieran J. Rothnie, Robert P. Wood, Victoria L. Banks, Lucinda J. Camidge, Alexandrosz Czira, Chris Compton, Raj Sharma, Shannon N. Millard, Olivia Massey, David M. G. Halpin
Publikováno v:
Respiratory Research, Vol 24, Iss 1, Pp 1-14 (2023)
Abstract Background Triple therapy is recommended for patients with chronic obstructive pulmonary disease (COPD) who remain symptomatic despite dual therapy. The optimal timing of triple therapy following an exacerbation of COPD is unknown. The outco
Externí odkaz:
https://doaj.org/article/c70b024ce5e54c2f9ecfb83345d017c1
Autor:
Afisi S. Ismaila, Kieran J. Rothnie, Robert P. Wood, Victoria L. Banks, Lucinda J. Camidge, Alexandrosz Czira, Chris Compton, Raj Sharma, Shannon N. Millard, Olivia Massey, David M. G. Halpin
Publikováno v:
Respiratory Research, Vol 25, Iss 1, Pp 1-2 (2024)
Externí odkaz:
https://doaj.org/article/c9d8ba6101bc483b9b8fbd6c5f1f2017
Autor:
Alan Martin, Dhvani Shah, Kerigo Ndirangu, Glenn A. Anley, Gabriel Okorogheye, Melanie Schroeder, Nancy Risebrough, Afisi S. Ismaila
Publikováno v:
ERJ Open Research, Vol 8, Iss 1 (2022)
Background The IMPACT trial demonstrated superior outcomes following 52 weeks of once-daily single-inhaler treatment with fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) (100/62.5/25 μg) compared with once-daily FF/VI (100/25 μg) or UM
Externí odkaz:
https://doaj.org/article/d24b893fc70949e9a4aed4830719690e
Autor:
David M.G. Halpin, Sally Worsley, Afisi S. Ismaila, Kai-Michael Beeh, Dawn Midwinter, Janwillem W.H. Kocks, Elaine Irving, Jose M. Marin, Neil Martin, Maggie Tabberer, Neil G. Snowise, Chris Compton
Publikováno v:
ERJ Open Research, Vol 7, Iss 2 (2021)
Introduction Real-world trial data comparing single- with multiple-inhaler triple therapy (MITT) in COPD patients are currently lacking. The effectiveness of once-daily single-inhaler fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) and M
Externí odkaz:
https://doaj.org/article/eda65af7d9bd474f992bce2f9bd825cb
Autor:
Elisabeth Fenwick, Alan Martin, Melanie Schroeder, Stuart J. Mealing, Oyinkansola Solanke, Nancy Risebrough, Afisi S. Ismaila
Publikováno v:
ERJ Open Research, Vol 7, Iss 1 (2021)
UK management costs for COPD, estimated at £1.9 billion/year, are rising. In the FULFIL (Lung Function and Quality of Life Assessment in Chronic Obstructive Pulmonary Disease with Closed Triple Therapy) study, single-inhaler triple therapy with flut
Externí odkaz:
https://doaj.org/article/b2a0603e40884c9285740e142a5f2658
Autor:
Sally Worsley, Neil Snowise, David M.G. Halpin, Dawn Midwinter, Afisi S. Ismaila, Elaine Irving, Leah Sansbury, Maggie Tabberer, David Leather, Chris Compton
Publikováno v:
ERJ Open Research, Vol 5, Iss 4 (2019)
Effectiveness studies complement conventional randomised controlled trials by providing a holistic view of treatments in the setting of usual clinical practice. We present the protocol for the ongoing INTREPID (INvestigation of TRelegy Effectiveness:
Externí odkaz:
https://doaj.org/article/2991a2b300fb4a648e86aa3265cce6df
Autor:
Dhvani Shah, Maurice Driessen, Nancy Risebrough, Timothy Baker, Ian Naya, Andrew Briggs, Afisi S. Ismaila
Publikováno v:
Cost Effectiveness and Resource Allocation, Vol 16, Iss 1, Pp 1-10 (2018)
Abstract Background Cost-effectiveness of once-daily umeclidinium bromide (UMEC) was compared with once-daily tiotropium (TIO) and once-daily glycopyrronium (GLY) in patients with chronic obstructive pulmonary disease (COPD) from a UK National Health
Externí odkaz:
https://doaj.org/article/9f617592621f49199211fa6da830622f
Autor:
Peter R. Bremner, Ruby Birk, Noushin Brealey, Afisi S. Ismaila, Chang-Qing Zhu, David A. Lipson
Publikováno v:
Respiratory Research, Vol 19, Iss 1, Pp 1-10 (2018)
Abstract Background Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg has been shown to improve lung function and health status, and reduce exacerbations, versus budesonide/formoterol in patients with chronic obs
Externí odkaz:
https://doaj.org/article/ccd29838d82b4091a09d185b46fc79d5
Autor:
Ian Naya, Chris Compton, Afisi S. Ismaila, Ruby Birk, Noushin Brealey, Maggie Tabberer, Chang-Qing Zhu, David A. Lipson, Gerard Criner
Publikováno v:
ERJ Open Research, Vol 4, Iss 4 (2018)
Clinically important deterioration (CID) is a novel composite end-point (lung function, health status, exacerbations) for assessing disease stability in patients with chronic obstructive pulmonary disease (COPD). We prospectively analysed CID in the
Externí odkaz:
https://doaj.org/article/1c24a94a5bb24daeb8ac4f1810b76339
Autor:
Tam Dang-Tan, Shiyuan Zhang, Ruben V. Tavares, Melissa Stutz, Afisi S. Ismaila, Julie Vaillancourt, Diane Corriveau, Richard H. Stanford, Xiwu Lin, Gilbert A. Nadeau, Alexander Simidchiev, Daria Parsons, John S. Sampalis
Publikováno v:
Canadian Respiratory Journal, Vol 2017 (2017)
Background. Chronic obstructive pulmonary disease (COPD) prevalence in Canada has risen over time. COPD-related exacerbations contribute to the increased health care utilization (HCU) in this population. This study investigated the impact of exacerba
Externí odkaz:
https://doaj.org/article/2884f883900d450694172db2dab9e6ac